CytoMed Therapeutics Limited (GDTC) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -1.59M | -1.16M | -595.15K | -842.6K | -604.6K | -865.33K | -428.49K | -1.03M | -547.7K | -1.55M | -764.08K | -693.48K |
| Operating CF Margin % | -1220.25% | -1100.14% | -594.89% | -1607.56% | -556.63% | -1046.77% | -515.6% | -1210.68% | -669.99% | -1477.24% | -715.53% | -641.98% |
| Operating CF Growth % | -89.17% | -34.39% | -38.89% | 17.82% | -10.39% | 44.26% | 43.92% | -47.84% | -72.2% | -287.53% | -327.21% | 16.78% |
| Net Income | -1.35M | -1.69M | -835.04K | -522.91K | -555.68K | -401.34K | -403.48K | -748.22K | -722.26K | -797.9K | -810.82K | -797.34K |
| Depreciation & Amortization | 102.44K | 71.5K | 66.79K | 61.69K | 65.55K | 61.53K | 61.86K | 67.46K | 65.12K | 75.09K | 76.3K | 75.36K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -105.05K | 591.94K | 240.88K | -337.29K | -67.62K | -540.76K | -102.2K | -386.81K | 68.61K | -786.3K | 14.36K | 103.9K |
| Working Capital Changes | -245.01K | -131.37K | -67.78K | -44.09K | -46.85K | 15.24K | 15.32K | 42.3K | 40.84K | -43.22K | -43.92K | -75.39K |
| Change in Receivables | -294.52K | -137.58K | -67.78K | -44.09K | -46.85K | 15.24K | 15.32K | 42.3K | 40.84K | -43.22K | -43.92K | -75.39K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -27.83K | 27.7K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 664.65K | -69.97K | -8.4K | 1.9M | 1.17M | -1.4M | -699.82K | -2.08M | 998.15K | -12.82K | -2.05M | -30.69K |
| Capital Expenditures | -282.36K | -262.73K | -129.44K | -179.43K | -190.68K | -335.6K | -337.39K | -15.6K | -15.06K | -6.33K | -6.43K | -19.31K |
| CapEx % of Revenue | 216.16% | 248.55% | 129.38% | 342.33% | 175.55% | 405.97% | 405.97% | 18.42% | 18.42% | 6.03% | 6.03% | 17.87% |
| Acquisitions | 542.61K | 46 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 352 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 121.04K | 2.08M | 1.36M | -1.07M | -362.43K | -2.07M | 1.01M | -6.49K | -2.04M | -11.74K |
| Cash from Financing | 196.51K | -18.55K | -12.98K | -18.97K | -13.75K | -14.65K | -10.95K | -78.42K | -187 | 8.2M | 4.1M | 813.6K |
| Debt Issued (Net) | -15.72K | -14.12K | 0 | -14.37K | 0 | -11.86K | 0 | 8.9K | 0 | -255.57K | 0 | -277.51K |
| Equity Issued (Net) | 219.46K | 0 | 0 | 0 | 0 | 0 | 0 | -85.06K | 0 | 8.46M | 0 | 1.09M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -7.23K | -4.43K | -12.98K | -4.6K | -13.75K | -2.79K | -10.95K | -2.27K | -187 | -3.24K | 4.1M | -2.27K |
| Net Change in Cash | -612.09K | -1.2M | 0 | -979.7K | 0 | -2.4M | 0 | -893.47K | -3.69M | 3.69M | -1.18M | 1.18M |
| Free Cash Flow | -1.83M | -1.43M | -724.59K | -748.39K | -795.28K | -761.83K | -765.88K | -582.98K | -562.75K | -758.24K | -770.51K | -360.36K |
| FCF Margin % | -1397.67% | -1348.69% | -724.27% | -1427.81% | -732.18% | -921.56% | -921.57% | -688.41% | -688.41% | -721.56% | -721.55% | -333.6% |
| FCF Growth % | -143.95% | -87.13% | 5.39% | -28.37% | -41.32% | -0.47% | 0.6% | -61.78% | -67.45% | -132.34% | -130.31% | 41.06% |
| FCF per Share | -0.15 | -0.12 | -0.06 | -0.06 | -0.07 | -0.07 | -0.07 | -0.05 | -0.05 | -0.07 | -0.08 | -0.03 |
| FCF Conversion (FCF/Net Income) | 1.18x | 1.32x | 0.71x | 0.78x | 1.09x | 1.07x | 1.06x | 1.37x | 0.76x | 0.96x | 0.94x | 0.45x |
| Interest Paid | 0 | 0 | 0 | 0 | 4.09K | 0 | 3.63K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |